摘要 |
Ophthalmic formulations are provided. The ophthalmic formulations include one or more active agents that act to optimize pupil light reflex while minimizing, or effectively eliminating, any undesired eye redness in response to application thereof. The active agents include, for example, alpha 1 antagonists, such as alpha 1a selective antagonists. |
主权项 |
1. An ophthalmic formulation in an emulsified form for topical administration, the ophthalmic formulation comprising:
a sterile aqueous carrier including an ophthalmic artificial tear solution, and a therapeutically effective amount of an alpha 1 antagonist that selectively effects an iris alpha adrenergic receptor over a vascular alpha adrenergic receptor for optimizing a pupil diameter in a reduced light while minimizing eye redness, wherein the alpha 1 antagonist is selected from the group consisting of sulfonamides including tamsulosin; uracils including A-131701, fiduloxasin, Ro-70-004, urapidil and 5-methyl urapidil; piperidines including 4-oxospiro benzopyran-2,4-piperidine; arylpiperazines including RWJ-38063, RWJ-68141, RWJ-68157, RWJ-69736, Ro-70-004, REC 15/2739, SB216469, urapidil and 5-methyl urapidil; dihydropyridines including SNAP 5089 and niguldipine; aminobenzodioxanes including WB 4101; dihydroindoles including RS 17053; n-alkylated saccharins; and derivatives thereof. |